Seung-Wan Ryu, surgeon, Keimyung University, Dongsan Hospital in Daegu, Korea

Biography
Dr. Seung-Wan Ryu serves as the Director of the Division of Gastrointestinal Surgery at Keimyung University Dongsan Hospital in Daegu, South Korea. He is also a distinguished Professor at the Dongsan Obesity & Metabolic Surgery Center (DOME), where he specializes in advanced laparoscopic procedures for the treatment of gastrointestinal diseases, with a particular emphasis on gastric cancer and obesity management.
His career is marked by a deep commitment to the surgical community, holding presidency roles in prestigious societies such as the Korean Laparoscopic GI Surgery Study Group (KLASS), Korean Society for Metabolic and Bariatric Surgery (KSMBS), and the Korean Society of Surgical Metabolism and Nutrition (KSSMN). Additionally, Dr. Ryu is a pivotal member of the Korean Surgical Society, serving as the Director of the Public Relation Committee, and the Korean Society for Parenteral and Enteral Nutrition, where he oversees the Planning Committee.
Dr. Ryu’s contributions to the field are recognized both nationally and internationally, making him a leading figure in gastrointestinal surgery and a prominent voice in discussions on surgical treatments for gastric cancer and obesity.
Summary of presentation
As the current president of the Korean Laparoendoscopic Gastrointestinal Surgery Study Group (KLASS), it is my privilege to present an overview of the significant contributions KLASS has made to the field of gastric cancer surgery. Established in 2004, KLASS began its first trial, KLASS 01, in 2006, focusing on pioneering laparoscopic techniques for gastric cancer treatment. This trial series has now expanded to its 14th iteration as of December 2024. To date, KLASS trials have produced approximately 36 scholarly papers, many of which are pivotal publications featured in high-impact journals, These works have played a crucial role in shaping current surgical practices and have been instrumental in the development of gastric cancer treatment guidelines not only in Korea but also in Japan and China. The influence of KLASS extends beyond national borders, setting benchmarks in clinical excellence and surgical innovation. Our trials are meticulously designed and executed, ensuring that each study contributes valuable insights into the safety, efficacy, and outcomes of laparoscopic procedures for gastric cancer. Through our clllaborative efforts with esteemed seniors, colleagues, and numerous clinical researchers, KLASS continues to spearhead research initiatives that push the boundaries of what is possible in medical science. Our ongoing research projects aim to further refine surgical techniques, enhance patient recovery, and ultimately improve survival rates. This presentation will detail the evolution of KLASS trials, highlight key findings from our extensive body of research, and discuss current trials that are setting new frontiers in the treatment of gastric cancer. By sharing oru experiences and insights, we hope to contribute to the global discourse on cancer treatment and inspire further advancements in thd field.
- Parallel session 1, Parallel session 2, Parallel session 3
Current trials in Korea
Date: 08 May 2025Time: 08:45 - 09:00 CET